awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q48164214-66B3881A-17B0-4258-97F0-AA360A2F240D
Q48164214-66B3881A-17B0-4258-97F0-AA360A2F240D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48164214-66B3881A-17B0-4258-97F0-AA360A2F240D
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
P2860
Q48164214-66B3881A-17B0-4258-97F0-AA360A2F240D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48164214-66B3881A-17B0-4258-97F0-AA360A2F240D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3d1c537ebca3a1f22cd88181f8d7b13040e5d1a8
P2860
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.